Chemotherapy with or without immunotherapy for advanced stomach or esophagus cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares two chemotherapy combinations, with or without an immunotherapy drug called nivolumab, for people with advanced stomach, esophagus, or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see which treatment works better and if adding immunotherapy helps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic cancer of the stomach, esophagus, or where the esophagus meets the stomach.
- Your cancer is HER2 negative and your PD-L1 status is known.
- You have not had chemotherapy or other systemic treatment for advanced or metastatic disease.
- If you had chemotherapy or immunotherapy before surgery (neoadjuvant) or after surgery (adjuvant), it must have finished at least 1 year ago.
- You are 18 years or older and able to perform daily activities (ECOG 0 or 1).
- Your blood counts, kidney, and liver function are within acceptable ranges.
- You are not pregnant or nursing, and if you could become pregnant, you agree to use birth control.
- You do not have untreated brain metastases or active autoimmune disease requiring systemic treatment.
- You have not had an organ or tissue transplant.
- You do not have significant nerve damage (neuropathy) or certain heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
This trial tests a combination of three drugs for advanced stomach or esophagus cancer that hasn't been treated much. The goal is to see if this combination helps shrink or control the cancer.
This trial tests whether adding the immunotherapy drug nivolumab to standard treatment works better for advanced stomach or esophageal cancer. It is for people whose cancer has already progressed after a first round of chemo plus immunotherapy.
This trial tests a shorter course of radiation combined with chemotherapy (FOLFOX) before surgery for esophageal or stomach-junction cancer. It aims to reduce side effects and still improve outcomes.
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
Hear when a new Advanced Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.